Literature DB >> 1873588

Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation.

A Bosi1, A M Vannucchi, A Grossi, S Guidi, L Vannucchi, R Saccardi, P A Bernabei, G Longo, D Rafanelli, P Rossi-Ferrini.   

Abstract

Serum erythropoietin (sEpo) levels were serially measured with a radioimmunoassay in 14 patients undergoing autologous bone marrow transplantation (BMT), starting before the institution of the conditioning regimen up to day +45. An increase in sEpo levels was observed soon after starting the chemotherapy regimen, and before an evident fall in hemoglobin (Hb) levels took place. The peak in sEPo levels (221 +/- 181 mU/ml) was reached at day 0 in 9/14 patients, and was delayed up to day + 10 in the remaining five. There was a negative correlation between loge sEpo and Hb values (r = -0.730; p less than 0.01); the regression line of this correlation was comparable to the one obtained in a group of 15 iron-deficiency anemic subjects. Therefore, patients undergoing autologous BMT appear to be able to develop adequately increased sEpo levels in response to the severity of anemia. No correlation was found between sEpo and white blood cell or platelet count. On the other hand, sEpo value at day 0 was significantly related to the day of neutrophil recovery (r = -0.806; p less than 0.001): patients with the highest sEpo levels at day 0 showed significantly faster (p less than 0.001) neutrophil recovery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873588

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Effect of recombinant human erythropoietin after allogenic bone marrow transplantation.

Authors:  H Link; T Brune; G Hübner; H Diedrich; M Freund; M Stoll; D Peest; W Ebell; C Bettoni; W Oster
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

Review 2.  Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.

Authors:  A Markham; H M Bryson
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.